Tocilizumab + Prednisone + Tocilizumab Placebo + Prednisone Placebo + Corticosteroids + Methotrexate
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Giant Cell Arteritis
Conditions
Giant Cell Arteritis
Trial Timeline
Jul 22, 2013 → Jun 4, 2018
NCT ID
NCT01791153About Tocilizumab + Prednisone + Tocilizumab Placebo + Prednisone Placebo + Corticosteroids + Methotrexate
Tocilizumab + Prednisone + Tocilizumab Placebo + Prednisone Placebo + Corticosteroids + Methotrexate is a phase 3 stage product being developed by Roche for Giant Cell Arteritis. The current trial status is completed. This product is registered under clinical trial identifier NCT01791153. Target conditions include Giant Cell Arteritis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01791153 | Phase 3 | Completed |
Competing Products
20 competing products in Giant Cell Arteritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| prednisone | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| Pexidartinib | Daiichi Sankyo | Phase 2 | 52 |
| Pexidartinib | Daiichi Sankyo | Phase 3 | 77 |
| Pexidartinib | Daiichi Sankyo | Approved | 85 |
| Baricitinib | Eli Lilly | Phase 2 | 52 |
| Upadacitinib + Corticosteroid (CS) | AbbVie | Phase 3 | 77 |
| dovitinib | Novartis | Phase 2 | 52 |
| Secukinumab 300 mg, s.c. + Placebo to match Secukinumab, s.c. | Novartis | Phase 3 | 77 |
| Secukinumab 300 mg, s.c. + Prednisolone + Placebo | Novartis | Phase 2 | 52 |
| Secukinumab | Novartis | Phase 1 | 33 |
| Secukinumab 300 mg + Secukinumab 150 mg | Novartis | Phase 3 | 77 |
| Tocilizumab + Placebo | Roche | Phase 3 | 77 |
| Tocilizumab + Prednisone | Roche | Approved | 85 |
| Tocilizumab | Roche | Phase 3 | 77 |
| Tocilizumab | Roche | Phase 1 | 33 |
| Valganciclovir | Roche | Approved | 85 |
| Tocilizumab + Glucocorticoids (GCs) + Placebo + Glucocorticoids (GCs) | Roche | Phase 2 | 52 |
| tocilizumab and IV steroids combination | Roche | Phase 2 | 52 |
| Denosumab | Amgen | Approved | 84 |
| Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA] | Amgen | Phase 2 | 51 |